This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
By This Author:
« Back
Page 1 of 2

Pfizer Ponies Up to Develop Long-acting Growth Hormone

By Pamela Taulbee

Opko gains $295 million up front for global license to develop, market long-acting HGH.

11:38AM 12/16/14

Third Point's Daniel Loeb Tells Amgen it's Time to Break up

By Pamela Taulbee

Amgen plans to expound on plans for the company at its Oct. 28 investor meeting.

11:36AM 10/22/14

Changing hospital dynamic leads Becton Dickinson to buy CareFusion

By Pamela Taulbee

Cash, stock $12.2 billion deal would solidify BD position in infection control, respiratory care.

02:28PM 10/06/14

Amag, Perrigo Buy Lumara in Two-Step Deal Valued at $1.1B

By Pamela Taulbee

Perrigo gains women's health assets, Amag Pharmaceuticals buys Makena line in the transaction.

11:13AM 09/29/14

Auxilium Adopts Poison Pill in Response to $2.2B Endo Bid

By Pamela Taulbee

The unsolicited bid comes a week after the Pennsylvania target announced a plant to cut 30% of its workforce.

11:50AM 09/17/14

Cognizant Expands Healthcare Information Technology With $2.7B Trizetto Buy

By Pamela Taulbee

Teaneck, N.J.-based information technology solutions company Cognizant Technology Solutions is adding the operations of TriZetto to create a fully integrated healthcare technology and operations leader.

11:08AM 09/15/14

Roche, InterMune a Strategic Play in Midst of Inversions

By Pamela Taulbee

As more companies seek tax savings through inversions, strategic reasons still remain for drug company deals.

09:19AM 08/27/14

Pfizer Bolsters Injectables by Buying InnoPharma

By Pamela Taulbee

Fresh from AstraZeneca plc's rebuff of its $117 billion offer, Pfizer is setting its sights on a much smaller deal in the U.S. by acquiring InnoPharma.

10:17AM 07/17/14

St. Jude Medical Pays $200M for NeuroTherm

By Pamela Taulbee

Target produces radiofrequency ablation systems, boosting the buyer's pain management business.

09:44AM 07/15/14

Salix to Invert, Merging With Cosmo Pharma

By Pamela Taulbee

Building on the M&A trend for tax inversion deals, Salix Pharmaceuticals and Italy's Cosmo Pharmaceuticals plan to merge.

01:05PM 07/09/14

« Back
Page 1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs